KEYNOTE-021 cohorts D and H suggest modest benefit in combining ipilimumab with pembrolizumab in second-line or later advanced non-small cell lung cancer treatment

Benzer Materyaller

• KEYNOTE-042 rolls back programmed cell death ligand 1 threshold for non-small cell lung cancer pembrolizumab monotherapy without new insight into those deriving benefit
  Yazar:: Cummings, Amy Lauren, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Extended follow-up on KEYNOTE-024 suggests significant survival benefit for pembrolizumab in patients with PD-L1 ≥50%, but unanswered questions remain
  Yazar:: Pacheco, Jose M., ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Prolonged benefit from ipilimumab correlates with improved outcomes from subsequent pembrolizumab
  Yazar:: Shreders, Amanda, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• Commentary: 2-year follow up of pembrolizumab as second-line therapy for advanced urothelial cancer (“KEYNOTE 045”)
  Yazar:: Fishman, Mayer
  Baskı/Yayın Bilgisi: (2019)
• Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study
  Yazar:: Gadgeel, Shirish M., ve diğerleri
  Baskı/Yayın Bilgisi: (2018)